[1]苏雯琪,胡立影,李筱荣,等.复方樟柳碱注射液治疗慢性中心性浆液性脉络膜视网膜病变的临床研究[J].眼科新进展,2018,38(12):1137-1140.[doi:10.13389/j.cnki.rao.2018.0268]
　SU Wen-Qi,HU Li-Ying,LI Xiao-Rong,et al.Clinical study of compound anisodine injection in the treatment of chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2018,38(12):1137-1140.[doi:10.13389/j.cnki.rao.2018.0268]
点击复制

复方樟柳碱注射液治疗慢性中心性浆液性脉络膜视网膜病变的临床研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年12期
页码:
1137-1140
栏目:
应用研究
出版日期:
2018-12-05

文章信息/Info

Title:
Clinical study of compound anisodine injection in the treatment of chronic central serous chorioretinopathy
作者:
苏雯琪; 胡立影; 李筱荣; 李志清
300110　天津市，天津医科大学眼科医院
Author(s):
SU Wen-Qi; HU Li-Ying; LI Xiao-Rong; LI Zhi-Qing
Eye Hospital，Tianjin Medical University，Tianjin 300110，China
关键词:
中心性浆液性脉络膜视网膜病变; 复方樟柳碱注射液; 光学相干断层扫描; 光学相干断层扫描血管造影; 血流密度; 视网膜色素上皮
Keywords:
central serous chorioretinopathy; compound anisodine; OCT; OCTA; vessel density;  retinal pigment epithelial
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0268
文献标志码:
A
摘要:
目的　研究复方樟柳碱注射液治疗慢性中心性浆液性脉络膜视网膜病变（central serous chorioretinopathy，CSC）的有效性及安全性。方法　非随机同期对照研究。收集慢性CSC患者，根据入选标准和排除标准将研究对象分成复方樟柳碱注射液颞浅动脉旁注射联合常规药物治疗组（治疗组）及单纯常规药物治疗组（对照组）。通过观察治疗后3个月及6个月视力、光学相干断层扫描（optical coherence tomography，OCT）及光学相干断层扫描血管造影（optical coherence tomography angiography，OCTA）图像及通过手动测量及Image J量化OCTA图像，比较两组最佳矫正视力、视网膜下液面积、黄斑区脉络膜毛细血管层血流密度较基线的改变均值。结果　对照组10例11眼，治疗组17例18眼。两组年龄、性别匹配。治疗后3个月、6个月治疗组最佳矫正视力较基线提升比对照组明显（P＜0.01）；治疗后3个月、6个月时治疗组与对照组黄斑区视网膜下液面积较基线均下降，但治疗组治疗后6个月内视网膜下液面积持续下降；治疗组在治疗后3个月、6个月时，脉络膜毛细血管层血流密度较基线明显增加，且与对照组有明显差异（P＜0.05）。结论　复方樟柳碱注射液在治疗慢性CSC中可以促进视网膜下液吸收和脉络膜毛细血管血液循环，增加血流密度，改善视网膜深层及脉络膜缺血状态，有效提高慢性CSC患者的视力。
Abstract:
Objective　To study the efficacy and safety of compound anisodine (CA) injection in the treatment of chronic central serous chorioretinopathy (CSC). Methods　A non-randomized simultaneous controlled study. Patients with chronic serous chorioretinopathy were collected. According to the inclusion criteria and exclusion criteria, the subjects were divided into two groups: CA injection combined with conventional drug therapy group and simple conventional drug treatment group. The experimental group received at least two courses of injection, and the course of injection could be increased according to the need. By observing the OCT and OCTA images of the two groups after 3 and 6 months of treatment, the best corrected visual acuity (BCVA), the area of subretinal fluid (SRF), the vessel density of the choriocapillaries layer （CCL） in the macula were tested.Results　Total 10 patients (11 eyes) were treated with conventional drugs, and 17 patients (18 eyes) were treated with CA injection combined with conventional drug therapy. There was no significant difference in baseline between the two groups. The improvement of BCVA in the treatment group was significantly higher than that in the control group in 3 months and 6 months compared with the baseline (P<0.01). At 6 months, the area of SRF in treatment group and control group were both decreased comparing with baseline. However, the decreased area of SRF in the treatment group was sustaining during 6 months. The vessel density of CCL was significantly higher than that of the baseline at 3 and 6 months after treatment, and there was a significant difference between the two groups (P<0.05). Conclusion　CA injection can promote the absorption of SRF and increase CCL vessel density at 6 months. Thus, we consider that CA injection combined with conventional drug therapy can relieve the choroidal ischemic state of chronic CSC so that the BCVA of patients with chronic CSC can be improved effectively. The safety of CA injection was confirmed by no adverse events in treatment group.

参考文献/References:

［1］　PRUNTE C，FLAMMER J.Choroidal capillary and venous congestion in central serous chorioretinopathy［J］.Am J Ophthalmol，1996，121 （1）：26-34.
［2］　SCHEIDER A，NASEMANN J E，LUND O E.Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy［J］.Am J Ophthalmol，1993，115 （1）：50-56.
［3］　LUO T，CHEN L H.Compoud anisodine in the treatment of central serous chorioretinopathy：clinical observation ［J］.Chin Pharma，2008，19（26）：2044-2046.
罗彤，陈丽华.复方樟柳碱治疗中心性浆液性脉络膜视网膜病变的疗效观察［J］.中国药房，2008，19（26）：2044-2046.
［4］　GUAN Q X.Clinical observation of compoud anisodine in the treatment of central serous chorioretinopathy［J］.J Front Medic，2014，23（32）：154-155.
管清霞.复方樟柳碱注射液治疗中心性浆液性脉络膜视网膜病变疗效观察［J］.医药前沿，2014，23（32）：154-155.
［5］　MA L L.Clinical observation of compoud anisodine in the treatment of central serous chorioretinopathy［J］.Chin Remed Clin，2012，12（3）：389-390.
马利利.复方樟柳碱治疗中心性浆液性脉络膜视网膜病变的疗效观察［J］.中国药物与临床，2012，12（3）：389-390.
［6］　LONG F，CAO S J，WANG L P.Study in krypton laser combined with compound ansodine for central serous chorioretinopathy［J］.Int Eye Sci，2011，11（2）：330-331.
龙飞，曹书杰，王立平.氪黄激光联合复方樟柳碱治疗中心性浆液性脉络膜视网膜病变［J］.国际眼科杂志，2011，11（2）：330-331.
［7］　WANG T T，XU G X.Clinical observation of alliance application of compound anisodine and joletion in the treatment of central serous chorioretinopathy［J］.Int Eye Sci，2009，9（6）：1169-1171.
王婷婷，徐国兴.复方樟柳碱联合沃丽汀治疗中心性浆液性脉络膜视网膜病变的疗效观察［J］.国际眼科杂志，2009，9（6）：1169-1171.
［8］　LIU X，DU J，CHENG C，WANG N，ZHONG M R，WU J K，et al.Clinical analysis of compound anisodine injection combined with iodized Lecithin Tablets in treatment of central serous chorioretinopathy［J］.Drug Evaluat Res，2017，40（2）：249-251.
刘萱，杜鹃，程橙，王妮，仲萌睿，吴江坤，等.复方樟柳碱联合卵磷脂络合碘片对中心性浆液性脉络膜视网膜病变的临床观察［J］.药物评价研究，2017，40（2）：249-251.
［9］　MARUKO I，IIDA T，SUGANO Y，OJIMA A，SEKIRYU T.Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy［J］.Retina，2011，31（8）：1603-1608.
［10］　IMAMURA Y，FUJIWARA T，MARGOLIS R，SPAIDE R F.Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy［J］.Retina，2009，29（10）：1469-1473.
［11］　TITTL M，POLSKA E，KIRCHER K，KRUGER A，MAAR N，STUR M，et al.Topical fundus pulsation measurement in patients with active central serous chorioretinopathy［J］.Arch Ophthalmol，2003，121（7）：975-978.
［12］　TITTL M，MAAR N，POLSKA E，WEIGERT G，STUR M，SCH-METTERER L.Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy［J］.Invest Ophthalmol Vis Sci，2005，46（12）：4717-4721.
［13］　SAITO M，NODA K，SAITO W，ISHIDA S.Relationship between choroidal blood flow velocity and choroidal thickness in patients with regression of acute central serous chorioretinopathy［J］.Graefes Arch Clin Exp Ophthalmol，2018，256（1）：227-229.
［14］　OKUSHIBA U，TAKEDA M.Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography （in Japanese）［J］.Nihon Ganka Gakkai Zasshi，1997，101（1）：74-82.
［15］　PRNTE C，FLAMMER J.Choroidal capillary and venous congestion in central serous chorioretinopathy［J］.Am J Ophthalmol，1996，121（1）：26-34.
［16］　SPAIDE R F，HALL L，HAAS A，CAMPEAS L，YANNUZZI L A，FISHER Y L，et al.Indocyanine green videoangiography of older patients with central serous chorioretinopathy［J］.Retina，1996，16（3）：203-213.
［17］　GUYER D R，YANNUZZI L A，SLAKTER J S，SORENSON J A，HO A，ORLOCK D.Digital indocyanine green videoangiography of central serous chorioretinopathy［J］.Arch Ophthalmol，1994，112（8）：1057-1062.
［18］　HAYASHI K，HASEGAWA Y，TOKORO T.Indocyanine green angiography of central serous chorioretinopathy［J］.Int Ophthalmol，1986，9（1）：37-41.
［19］　SCHEIDER A，NASEMANN J E，LUND O E.Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy［J］.Am J Ophthalmol，1993，115（1）：50-56.

相似文献/References:

[1]刘卫华 杨新怀 黄勤 聂鑫 覃旭方 全婵娟.OCT与FFA在中心性浆液性脉络膜视网膜病变检查中的应用比较[J].眼科新进展,2013,33(9):000.
[2]张鹏 王雨生 胡丹 王海燕 张自峰.561nm 激光光凝治疗中心性浆液性脉络膜视网膜病变[J].眼科新进展,2013,33(3):000.
[3]童桂芳 周琼.中心性浆液性脉络膜视网膜病变的研究进展[J].眼科新进展,2013,33(3):000.
[4]唐风雷 朱珊梅 周建强 于忠兴 朱太春 谢秀雯 蒋星 陆人杰.中心性浆液性脉络膜视网膜病变的临床研究与治疗评价[J].眼科新进展,2013,33(11):000.
[5]王志立 李晓华 李士清 董应丽 李萍. 慢性迁延性中心性浆液性脉络膜视网膜病变的两种自发荧光特征[J].眼科新进展,2014,34(2):151.
[6]徐建锋 叶瑞珍 李贵洲 蔡泽煌. 低能量TTT治疗中心凹下渗漏型CSC的临床研究[J].眼科新进展,2014,34(3):239.
[7]黄丽华,陈素芳,邵毅,等. 非诺贝特治疗中心性浆液性脉络膜视网膜病变的临床研究[J].眼科新进展,2014,34(4):333.[doi:10.13389/j.cnki.rao.2014.0090]
[8]林杜生,张贵华,陈浩宇,等. 频域OCT在急性Vogt-小柳原田病和急性中心性浆液性脉络膜视网膜病变鉴别诊断中的应用[J].眼科新进展,2015,35(6):557.[doi:10.13389/j.cnki.rao.2015.0151]
　LIN Du-Sheng,ZHANG Gui-Hua,CHEN Hao-Yu,et al. Distinguishing acute Vogt-Koyanagi-Harada disease from acute central serous chorioretinopathy with spectral domain OCT[J].Recent Advances in Ophthalmology,2015,35(12):557.[doi:10.13389/j.cnki.rao.2015.0151]
[9]童桂芳,周琼,邵毅. 急性中心性浆液性脉络膜视网膜病变FFA与频域OCT图像对比研究[J].眼科新进展,2015,35(8):735.[doi:10.13389/j.cnki.rao.2015.0201]
　TONG Gui-Fang,ZHOU Qiong,SHAO Yi. A comparative study on image of FFA and FD-OCT in acute central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2015,35(12):735.[doi:10.13389/j.cnki.rao.2015.0201]
[10]游慧,张学东.激光治疗中心性浆液性脉络膜视网膜病变的新进展[J].眼科新进展,2016,36(3):297.[doi:10.13389/j.cnki.rao.2016.0081]
　YOU Hui,ZHANG Xue-Dong.Recent advances in laser for central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2016,36(12):297.[doi:10.13389/j.cnki.rao.2016.0081]

备注/Memo

备注/Memo:
国家自然科学基金面上项目（编号：81670875）；天津市自然科学基金项目（编号：17JCYBJC27200、18JCQNJC10700）
更新日期/Last Update: 2018-12-04